AbbVie Inc., a biopharmaceutical company, has released preliminary financial results for the first quarter of 2024, including an update on its earnings guidance. The company expects to report acquired IPR&D and milestones expense of $164 million on a pre-tax basis, which will negatively impact both GAAP and non-GAAP diluted earnings per share by $0.08. These results are not yet finalized and are subject to financial statement closing procedures. AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.97 to $11.17, reflecting the impact of the first quarter expenses. The first quarter adjusted diluted earnings per share guidance is set between $2.18 and $2.22, inclusive of the acquired IPR&D and milestones expense. The company's guidance for the remainder of the year excludes any potential acquired IPR&D and milestones expense due to the unpredictable nature of such transactions. AbbVie's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.

AbbVie Inc., a biopharmaceutical company, has released preliminary financial results for the first quarter of 2024, including an update on its earnings guidance. The company expects to report acquired IPR&D and milestones expense of $164 million on a pre-tax basis, which will negatively impact both GAAP and non-GAAP diluted earnings per share by $0.08. These results are not yet finalized and are subject to financial statement closing procedures. AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.97 to $11.17, reflecting the impact of the first quarter expenses. The first quarter adjusted diluted earnings per share guidance is set between $2.18 and $2.22, inclusive of the acquired IPR&D and milestones expense. The company's guidance for the remainder of the year excludes any potential acquired IPR&D and milestones expense due to the unpredictable nature of such transactions. AbbVie's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.